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Introduction {#jcpp13161-sec-0005}
============

Attention‐deficit/hyperactivity disorder (ADHD) is a neuropsychiatric disorder with a high prevalence, affecting 5%--6% of children and 2.5%--4.9% of adults (Faraone et al., [2015](#jcpp13161-bib-0010){ref-type="ref"}). Individuals with this disorder are at high risk of developing comorbid psychiatric disorders across the entire life span (Franke et al., [2018](#jcpp13161-bib-0013){ref-type="ref"}). Twin and adoption studies have shown that ADHD is highly heritable, with heritability estimates of approximately 80% in both children and adults (Faraone et al., [2005](#jcpp13161-bib-0011){ref-type="ref"}; Larsson et al., [2014](#jcpp13161-bib-0030){ref-type="ref"}). ADHD is a clinically and etiologically heterogeneous disorder with a complex, multifactorial background. The identification of genes affecting the disorder has been challenging (Demontis et al., [2019](#jcpp13161-bib-0007){ref-type="ref"}; Franke et al., [2012](#jcpp13161-bib-0012){ref-type="ref"}; Gizer et al., [2009](#jcpp13161-bib-0015){ref-type="ref"}). In the last decade, genome‐wide association studies (GWAS) have been performed with increasing sample sizes. The first genome‐wide significant risk variants for ADHD from a GWAS meta‐analysis have recently been reported, all of which have small individual effect sizes (Demontis et al., [2019](#jcpp13161-bib-0007){ref-type="ref"}). In addition to studies of common genetic variants contributing to ADHD, other studies have focused on rare variants, which potentially have larger effect sizes. First exome sequencing studies are coming available (Corominas et al., [2018](#jcpp13161-bib-0004){ref-type="ref"}; Demontis et al., [2016](#jcpp13161-bib-0006){ref-type="ref"}; Hawi et al., [2016](#jcpp13161-bib-0020){ref-type="ref"}; Kim et al., [2017](#jcpp13161-bib-0027){ref-type="ref"}), but so far, most studies investigated copy‐number variations (CNVs) and identified rare CNVs in patients with ADHD (Akutagava‐Martins et al., [2014](#jcpp13161-bib-0001){ref-type="ref"}; Elia et al., [2010](#jcpp13161-bib-0008){ref-type="ref"}; Elia et al., [2011](#jcpp13161-bib-0009){ref-type="ref"}; Jarick et al., [2014](#jcpp13161-bib-0023){ref-type="ref"}; Lesch et al., [2011](#jcpp13161-bib-0032){ref-type="ref"}; Lesch et al., [2008](#jcpp13161-bib-0033){ref-type="ref"}; Martin et al., [2014](#jcpp13161-bib-0036){ref-type="ref"}; Ramos‐Quiroga et al., [2014](#jcpp13161-bib-0042){ref-type="ref"}; Williams et al., [2012](#jcpp13161-bib-0053){ref-type="ref"}; Williams et al., [2010](#jcpp13161-bib-0054){ref-type="ref"}; Yang et al., [2013](#jcpp13161-bib-0055){ref-type="ref"}). While most studies used case--control designs, CNVs have been identified in studies using a family‐based approach (Lesch et al., [2008](#jcpp13161-bib-0033){ref-type="ref"}). Now that first risk factors for ADHD have been identified from common and rare variant approaches, it has become evident that at least part of ADHD's comorbidity with disorders like major depression and psychotic disorders, such as bipolar disorder and schizophrenia, is based on genetic factors (Demontis et al., [2019](#jcpp13161-bib-0007){ref-type="ref"}; van Hulzen et al., [2017](#jcpp13161-bib-0051){ref-type="ref"}; Lee et al., [2013](#jcpp13161-bib-0031){ref-type="ref"}).

If a variant is only seen once in a case--control study of rare variants or in a single family, it is challenging to demonstrate the association with a psychiatric phenotype based on statistics. Similarly, in studies of common genetic risk factors for psychiatric phenotypes, it is often difficult to go beyond association and find evidence for the causal involvement of a specific gene, as variants tested through GWAS are just anonymous markers. An effective way forward in this is the use of suitable animal models, where one can specifically manipulate the expression of individual genes of interest. Around 75% of human genes have a clear orthologue in the fruit fly *Drosophila melanogaster* (van der Voet et al., [2014](#jcpp13161-bib-0050){ref-type="ref"}). The *Drosophila* model combines a vast genetic toolbox based on decades of research with a large range of quantifiable behaviors (van Alphen & van Swinderen, [2013](#jcpp13161-bib-0048){ref-type="ref"}) and is inexpensive in its use. We have recently shown that *Drosophila* is an appropriate model for ADHD; flies exhibited increased locomotor activity and decreased sleep upon dysregulation of validated ADHD candidate genes (van der Voet et al., [2016](#jcpp13161-bib-0049){ref-type="ref"}).

In this study, we used a multistep approach to identify and validate a novel risk gene for ADHD and comorbid psychiatric conditions. In a single family, severely affected by ADHD and comorbid disorders (especially psychosis), we applied genome‐wide single nucleotide polymorphism (SNP)‐based array analysis to detect rare copy number variants (CNVs) cosegregating with disease. Genes present in the CNV were tested -- as a set and individually -- for association with ADHD and other relevant psychiatric disorders based on common genetic variants, using the largest internationally available data sets. The significantly associated gene *FBXO25* was taken forward for functional validation in *Drosophila*. According to the nature of the CNV (copy number gain), we characterized the effects of CG11658 (*dFBXO25)* overexpression using locomotor activity and sleep behavior as functional readouts.

Methods and materials {#jcpp13161-sec-0006}
=====================

Study participants and cohorts {#jcpp13161-sec-0007}
------------------------------

### Dutch family {#jcpp13161-sec-0008}

The male index patient had diagnoses of ADHD, anxiety disorder, and multiple complex developmental disorder (MCDD) at the age of four years; he also showed aggressive behavior and suicidal tendencies, had experienced a psychotic episode, and reported somatic abnormalities including gastric reflux and clinodactyly (Appendix [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"}). His parents (mother diagnosed with ADHD, father without diagnosis), the mother's brother (psychotic episode, aggressive behavior, alcohol addiction, childhood ADHD symptoms, and currently homeless), the mother's sister (learning difficulties), and two of the mother's cousins (diagnosed with ADHD) were also ascertained for genetic testing (see Figure [1](#jcpp13161-fig-0001){ref-type="fig"} for the pedigree and Table [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"} and Appendix [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"} for more detailed description of psychiatric diagnoses and relevant symptoms). For these members of the family, saliva (using Oragene containers; DNA Genotek, Ottawa, ON, Canada) or blood was collected. All human material was collected after approval by the local ethic committees, and participants in this study gave written informed consent.

![Pedigree of the family investigated in this study. Patients with ADHD with or without psychiatric comorbidity are depicted in black (see Appendix [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"} and Table [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"} for an exhaustive description of their phenotypes), unaffected family members are shown by white symbols, and grey symbols represent family members with learning difficulties. The index patient is marked by a diagonal arrow. An asterisk beneath an individual's code indicates that DNA was used for qRT‐PCR analysis. The \# indicates that DNA was used for WES. ID = individual](JCPP-61-545-g001){#jcpp13161-fig-0001}

### GWAS meta‐analyses data sets for ADHD and schizophrenia {#jcpp13161-sec-0009}

We obtained genome‐wide association study meta‐analysis (GWAS‐MA) results in the form of summary statistics (*p*‐values and odds ratios) from the largest currently available data sets on ADHD and schizophrenia (SCZ). GWAS‐MA data on ADHD were obtained from the ADHD Working Group of the Psychiatric Genomics Consortium (PGC) and the ADHD iPSYCH‐SSI‐Broad collaboration. Data were downloaded from (<https://www.med.unc.edu/pgc/results-and-downloads>; *n* = 55,374; Demontis et al., [2019](#jcpp13161-bib-0007){ref-type="ref"}). GWAS‐MA data on schizophrenia were obtained from the SCZ working group of the PGC (*n* = 82,315; <https://www.med.unc.edu/pgc/results-and-downloads>; Schizophrenia Working Group of the Psychiatric Genomics Consortium, [2014](#jcpp13161-bib-0046){ref-type="ref"}). Only variants with an imputation quality score INFO \>0.8 and minor allele frequency (MAF) \>0.01 were taken forward for further analyses. Details of inclusion criteria, genotyping, and phenotype characteristics are described in the original publications (Demontis et al., [2019](#jcpp13161-bib-0007){ref-type="ref"}; Schizophrenia Working Group of the Psychiatric Genomics Consortium, [2014](#jcpp13161-bib-0046){ref-type="ref"}) and the Appendix [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"}.

Copy number analysis in the Dutch family {#jcpp13161-sec-0010}
----------------------------------------

Genome‐wide single nucleotide polymorphism (SNP)‐based array analysis was performed on DNA from peripheral blood of the index patient and his parents using the Affymetrix CytoScan HD array platform (Thermo Fisher Scientific, Waltham, MA) following the manufacturer's protocols. The probe values from 2.6 million markers, consisting of 750,000 SNPs and 1.9 million nonpolymorphic probes, were analyzed using the Affymetrix software package ChAS (Chromosome Analysis Suite) at an average resolution of approximately 20 kb and based on human genome build 37 (hg19). Detection and reporting criteria were used as previously described (Kooper et al., [2014](#jcpp13161-bib-0028){ref-type="ref"}). Follow‐up testing by fluorescence in situ hybridization (FISH) was performed with a subtelomeric 8pter probe (TelVysion 8p (D8S504); Abbott Molecular, Des Plaines, IL).

The observed CNV was subsequently confirmed by quantitative real‐time PCR (qRT‐PCR) in the index patient and his mother, and three additional family members were analyzed using this method. Genomic DNA was either isolated from saliva or from EDTA blood samples according to manufacturer's protocol at the department of Human Genetics of the Radboud University Medical Center, Nijmegen, The Netherlands. PrimeTime® Mini qRT‐PCR assay (Integrated DNA Technologies \[IDT\], Coralville, IA) was used to determine the copy number of *FBXO25* (for details see Appendix [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"}). Primer sequences are displayed in Table [S2](#jcpp13161-sup-0001){ref-type="supplementary-material"}. Results were analyzed with the 7500 Software v2.0.6 (Life Technologies) using an automatic threshold (Appendix [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"}). Data were visualized using GraphPad prism (version 5.03), and the mean and a 95% confidence interval are shown.

Gene‐set and gene‐based analyses in the PGC + iPSYCH ADHD and PGC schizophrenia data sets {#jcpp13161-sec-0011}
-----------------------------------------------------------------------------------------

The cumulative effect of common variants in the set of protein‐coding genes altered in the family (as a set and individually) was tested using summary statistics of the ADHD and the SCZ GWAS‐MA (Appendix [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"}; Demontis et al., [2019](#jcpp13161-bib-0007){ref-type="ref"}; Schizophrenia Working Group of the Psychiatric Genomics Consortium, [2014](#jcpp13161-bib-0046){ref-type="ref"}). Statistical analyses were performed using the Multi‐marker Analysis of GenoMic Annotation (MAGMA) software package (version 1.05; <http://ctglab.nl/software/magma>; de Leeuw et al., [2015](#jcpp13161-bib-0005){ref-type="ref"}) using the SNP‐wide mean model for gene‐based association analysis (for detailed description see Appendix [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"}). A correction for linkage disequilibrium (LD) was applied, based on the estimates from the 1,000 Genomes Phase 1 European ancestry samples (Genomes Project et al., [2010](#jcpp13161-bib-0014){ref-type="ref"}). Protein‐coding genes were considered gene‐wide significant, if they reached the Bonferroni‐corrected threshold adjusted for the number of genes tested (three tests; *p* \< .0167).

Brain gene expression {#jcpp13161-sec-0012}
---------------------

We determined the messenger‐RNA (mRNA) expression of genes located within the identified CNV. Using the publicly available data set provided by the Human Brain Transcriptome Project (Kang et al., [2011](#jcpp13161-bib-0026){ref-type="ref"}) at <http://hbatlas.org>, we assessed mRNA expression trajectories in six regions of the developing and adult human brain. Spanning periods from embryonic development to late adulthood, this data set provides genome‐wide exon‐level transcriptome data generated using the Affymetrix GeneChip Human Exon 1.0 SS Arrays from over 1,340 tissue samples from both hemispheres of postmortem human brains (*n* = 57)(GTEx Consortium, [2013](#jcpp13161-bib-0017){ref-type="ref"}).

Functional characterization of Fbxo25 in Drosophila {#jcpp13161-sec-0013}
---------------------------------------------------

### Drosophila stocks and maintenance {#jcpp13161-sec-0014}

Conditional overexpression of CG11658 (two‐to‐one orthologue of *FBXO25 and FBXO32*) was achieved by using the GAL4‐UAS system and the pan‐neuronal driver *UAS*‐Dcr‐2 hs(X); *nSyb*‐GAL4. UAS overexpression lines were obtained from the stock centers in Kyoto and Bloomington (Fbxo25 overexpression‐1: Kyoto stock 203566 and FBXO25 overexpression‐2: Bloomington stock 17663). The genetic background of the overexpression lines was isogenized for eight generations using a wild‐type Iso31 background (gift from A. Sehgal (Kumar et al., [2012](#jcpp13161-bib-0029){ref-type="ref"})). Flies were raised on standard medium (cornmeal, sugar, and yeast) and maintained on a 12 hours light dark cycle. Crosses with the pan‐neuronal driver UAS‐Dcr‐2 hs(X); nSyb‐Gal4 and the UAS overexpression lines were raised at 28°C. For the control condition, the same pan‐neuronal driver was crossed to the isogenic wild‐type background.

### Locomotor activity and sleep measurement {#jcpp13161-sec-0015}

Locomotor activity and sleep were assessed with the Drosophila Activity Monitor system (DAM), which measures locomotor activity by infrared photoelectric barriers (Trikinetics, Waltham, MA). Single adult flies were transferred to monitor tubes with standard food. Activity counts were collected in 30‐s bins and analyzed in 1‐min bins. Activity of individual 3--5 day‐old male flies was recorded over 4 days in a 12 hr light:dark cycle and subsequently 2 days in constant darkness. According to the standard in the field, five minutes of inactivity of a fly was defined as sleep. The analysis was performed with the pySolo software package (<https://www.pysolo.net/>), and activity and sleep in the light‐off period (relative night) (between 12 and 24 hr) were analyzed. Activity counts represent the amount of infrared detection beam passes of the fly. Statistical analysis was performed with the GraphPad Prism software package 5.03 for Windows (GraphPad Software, San Diego, CA, <http://www.graphpad.com>). *T*‐tests were performed, adding a Welch correction, when variances of groups were significantly different.

### Quantification of relative gene expression {#jcpp13161-sec-0016}

Flies carrying the inducible UAS element allowing for overexpression of CG11658 (isogenized strains of Bloomington 17663 and Kyoto 203566) and their isogenic controls were crossed to flies carrying the *yw*; *UAS*‐Dcr‐2 hs(X); *nSyb*‐GAL4 driver. Crosses were raised at 28°C. Per condition, three biological replicates of 10 heads of 3‐day‐old male flies were collected and snap frozen. RNA was extracted using the ARCTURUS PicoPure RNA Isolation Kit (Applied Biosystems, Waltham, MA), and total RNA concentration was measured with the Nanodrop (Thermo Fisher Scientific, Waltham, MA). Complementary cDNA was synthesized using iScript cDNA Synthesis Kit (Bio‐Rad, Hercules, CA). Relative gene expression per sample (three biological replicates) was quantified in technical triplicates using a powerSYBR Green PCR master mix (Applied Biosystems) on a 7900HT Real‐Time PCR Systems (Applied Biosystems). Crossing‐point (CP) values of the *CG11658* (dFBXO25) gene were normalized to the reference genes *αTub84B* and *elF‐1A*. For primer sequences see Table [S2](#jcpp13161-sup-0001){ref-type="supplementary-material"}.

Whole‐exome sequencing (WES) in Dutch family {#jcpp13161-sec-0017}
--------------------------------------------

Genomic DNA of the index patient and both parents isolated from blood was used for clinical whole‐exome sequencing (WES) to search for de novo mutations using protocols described previously (Neveling et al., [2013](#jcpp13161-bib-0039){ref-type="ref"}). The WES was performed in a diagnostic setting as part of the routine clinical assessment of the child. In short, exome capture was performed with the Agilent SureSelect Human All Exon enrichment kit v5 (Agilent Technologies, Santa Clara, CA). WES was performed on the Illumina HiSeq platform (BGI, Copenhagen, Denmark), and median target coverage was 100.2. Data were analyzed with Burrows--Wheeler Alignment (BWA) read alignment (Li & Durbin, [2009](#jcpp13161-bib-0034){ref-type="ref"}) and Genome Analysis Toolkit (GATK) variant calling (McKenna et al., [2010](#jcpp13161-bib-0037){ref-type="ref"}) software packages. Variants were annotated using an in‐house developed pipeline (Neveling et al., [2013](#jcpp13161-bib-0039){ref-type="ref"}). Prioritization of variants was done by an in‐house designed 'variant interface' and manual curation in line with international standards and guidelines for the interpretation of sequence variants (Richards et al., [2015](#jcpp13161-bib-0043){ref-type="ref"}). Only variants with a minimum coverage of 10 reads were considered for further analysis.

For an overview of the study flow, see Figure [S1](#jcpp13161-sup-0001){ref-type="supplementary-material"}.

Results {#jcpp13161-sec-0018}
=======

8p23.3 microduplication identified in a family with ADHD‐affected members {#jcpp13161-sec-0019}
-------------------------------------------------------------------------

In a family with several members affected with ADHD in the presence or absence of psychiatric comorbidity (Figure [1](#jcpp13161-fig-0001){ref-type="fig"}), SNP‐array analysis revealed that the index patient, his mother, and mother's brother carried a copy number gain of approximately 540 kb at the distal end of the short arm of chromosome 8 (arr\[hg19\] 8p23.3(158,049--541,637)x3), which spanned 590 probes (Figure [2](#jcpp13161-fig-0002){ref-type="fig"}). Follow‐up testing by FISH revealed that the gain in copy number was the result of a duplication rather than an unbalanced translocation. The microduplication encompassed three protein‐coding genes, *ZNF596*, *FBXO25*, and *TDRP*, and the pseudo‐gene *RPL23AP53*. The copy number gain was confirmed by qRT‐PCR through analysis of *FBXO25* (Figure [S2](#jcpp13161-sup-0001){ref-type="supplementary-material"}). The qRT‐PCR analysis showed that duplication of *FBXO25* was absent in one ADHD‐affected family member, but was present in the mother's sister, who had learning difficulties (Figure [S2](#jcpp13161-sup-0001){ref-type="supplementary-material"}).

![Microduplication of 8p23.3 in the index patient ID3‐2. (A) Array CGH plot of chromosome 8 of patient ID3‐2 with a terminal duplication of 535 kb in 8p23.3 spanning 590 probes (arr\[hg19\] 8p23.3(158,049--541,637)x3). Zoom‐in of this region is shown in panel (B). (C) Schematic representation of chromosome 8 with the 8p23.3 region enlarged in the lower part of the figure (screenshot of the UCSC Genome Browser Build 37/hg19; <http://genome.ucsc.edu/>); the small vertical bars show the probe coverage of the CytoScan HD array platform, the horizontal bars represent the genes in the duplicated 8p23.3 region (*RPL23AP53*, *ZNF596*, *FBXO25*, and *TDRP*)](JCPP-61-545-g002){#jcpp13161-fig-0002}

Common variants in the 8p23.3 locus are associated with ADHD {#jcpp13161-sec-0020}
------------------------------------------------------------

Focusing on protein‐coding genes within the 8p23.3 duplicated region (*ZNF596*, *FBXO25*, and *TDRP*), we performed a gene‐set analysis to provide additional evidence for a role of genetic variation in this region in ADHD and/or psychotic disorders, as several family members also showed psychotic symptoms. This was done using summary statistics of ADHD GWAS‐MA data of 20,183 patients with ADHD and 35,191 controls (Demontis et al., [2019](#jcpp13161-bib-0007){ref-type="ref"}) and SCZ GWAS‐MA summary statistics from the analysis of 34,241 cases and 45,604 controls (Schizophrenia Working Group of the Psychiatric Genomics Consortium, [2014](#jcpp13161-bib-0046){ref-type="ref"}). Joint analysis of the three genes showed significant association of the gene‐set with ADHD in both self‐contained and competitive tests (*p* ~self‐contained~ = .000184 and *p* ~competitive~ = .039151, see also Figure [S3](#jcpp13161-sup-0001){ref-type="supplementary-material"}a). No significance was observed for association with SCZ (*p* ~self‐contained~ = 0.7123 and *p* ~competitive~ = 0.90596, see also Figure [S3](#jcpp13161-sup-0001){ref-type="supplementary-material"}b).

To identify the most likely candidate gene for ADHD among the three protein‐coding genes in the microduplication, the genes were subsequently tested individually. Gene‐based analysis revealed that the two more proximal genes, *FBXO25* and *TDRP*, were significantly associated with ADHD (*p~FBXO25~* = .010756 and *p~TDRP~* = .000285; Table [S3](#jcpp13161-sup-0001){ref-type="supplementary-material"}).

Brain gene expression {#jcpp13161-sec-0021}
---------------------

We determined the distribution of mRNA expression for *FBXO25* and *TDRP* in the developing and adult human brain using data on six brain regions available from the Human Brain Transcriptome Project. As the mRNA expression figures in Figure [S4](#jcpp13161-sup-0001){ref-type="supplementary-material"} show, both genes appear to be widely expressed, both in the developing and the adult human brain.

Overexpression of the FBXO25 orthologue in Drosophila induces increased activity and reduced sleep {#jcpp13161-sec-0022}
--------------------------------------------------------------------------------------------------

To further establish the relevance of the associated genes as candidates for ADHD, we set out to study the effect of overexpression on ADHD‐relevant behavioral phenotypes in *Drosophila melanogaster*. Only *FBXO25* has a direct, as yet uncharacterized orthologue (*CG11658*) in the fruit fly, from now on referred as *Fbxo25*. As the duplication also includes the promoter region of *FBXO25*, we induced overexpression of *Fbxo25* using two unrelated *Drosophila* lines. Quantitative RT‐PCR confirmed the overexpression of this gene: in overexpression‐line 1, expression of *Fbxo25* was 450% compared with the control line; in overexpression‐line 2, it was 650%. Using earlier established tests of locomotor activity and sleep as ADHD‐relevant readouts (van der Voet et al., [2016](#jcpp13161-bib-0049){ref-type="ref"}), we found adult flies from either line to exhibit significantly elevated activity and reduced sleep in the relative night period (12 hr dark) compared with an appropriate genetic background control (Figure [3](#jcpp13161-fig-0003){ref-type="fig"}). In line with the qRT‐PCR results, overexpression‐line 2 showed the more severe behavioral phenotypes (Figure [3](#jcpp13161-fig-0003){ref-type="fig"}).

![Activity monitoring upon pan‐neuronal overexpression of the *FBXO25* orthologue in *Drosophila melanogaster*. (A) Activity and sleep profiles reveal increased activity (top graph) and decreased sleep (bottom graph) in the relative night (12--24 hr). (B) Quantification of the activity counts (amount of infrared detection beam passes) of individual flies in *FBXO25* overexpression--1 (*n* = 64) and overexpression--2 (*n* = 56) lines shows that the activity in the relative night is significantly and consistently higher in both compared with control (*n* = 63) flies (*FBXO25* overexpression--1: *p* = .0013; *FBXO25* overexpression‐2: *p* \< .0001). (C) Quantification of sleep in minutes of single flies shows that both *FBXO25* overexpression lines sleep significantly less in the relative night compared with control flies (*FBXO25* overexpression--1: *p* = .0076; *FBXO25* overexpression‐2: *p* \< .0001). \*\**p* \< .001, \*\*\**p* \< .0001](JCPP-61-545-g003){#jcpp13161-fig-0003}

Whole‐exome sequencing {#jcpp13161-sec-0023}
----------------------

Given the additional somatic features and early onset of severe psychiatric problems in the index patient, we performed clinical WES to identify additional rare variants that may contribute to the more severe clinical phenotype. Upon trio whole‐exome data analysis of the index patient and his parents, one de novo candidate variant was found in the index patient. This was a heterozygous insertion variant in *DUSP16* (c.813_814insGC \[p.Arg272fs\] \[GenBank: NM_030640.2\]) leading to a frameshift, located at the end of exon 5, it possibly affects the nearest splice site. This frameshift variant is not present in gnomAD (r.2.0.2, <https://gnomad.broadinstitute.org/>). Exploratory gene‐wide testing of common variants in *DUSP16* in the ADHD and SCZ GWAS‐MA data did not reveal evidence for association with ADHD (*p* = .39186), but the gene showed nominal association with schizophrenia (*p* = .0175).

Discussion {#jcpp13161-sec-0024}
==========

In this study, we identified and functionally validated a novel candidate gene for ADHD and comorbid psychiatric phenotypes. We report a microduplication in band p23.3 of chromosome 8, which segregated with a broad spectrum of psychiatric problems, including ADHD, in a family with several affected individuals in two generations. Common genetic variants in this locus were associated with ADHD risk; in particular, we observed significant gene‐based associations for the genes in the proximal part of the microduplication, *FBXO25,* and *TDRP*. One of the two genes, *FBXO25*, has an orthologue in *Drosophila melanogaster,* and we were able to confirm that its overexpression, as expected to arise from a copy number gain, leads to a night‐specific increase in locomotor activity and decrease in sleep. Since we have previously identified the same behavioral signature in several *Drosophila* models of ADHD (van der Voet et al., [2016](#jcpp13161-bib-0049){ref-type="ref"}) and similar phenotypes have also been suggested as readout for mania and circadian dysregulation (Guo et al., [2018](#jcpp13161-bib-0018){ref-type="ref"}; Padiath et al., [2004](#jcpp13161-bib-0040){ref-type="ref"}; Ries et al., [2017](#jcpp13161-bib-0044){ref-type="ref"}), these findings support *FBXO25* as a novel risk gene for ADHD and comorbid mental disorders.

The identified microduplication in 8p23.3 has not previously been reported in conjunction with ADHD or other neuropsychiatric disorders. A recent study combined data from eleven CNV studies that had identified rare CNVs occurring in patients with ADHD (Harich et al., [2019](#jcpp13161-bib-0019){ref-type="ref"}). We queried these existing data sources and found an additional ADHD patient, among 6,176 reported ones, who carried a duplication encompassing 77% of the *FBXO25* gene and including the promoter region. This duplication was not found in 25,026 controls (Elia et al., [2010](#jcpp13161-bib-0008){ref-type="ref"}; Harich et al., [2019](#jcpp13161-bib-0019){ref-type="ref"}).

The microduplication cosegregated with different psychiatric phenotypes, ranging from mild learning difficulties to ADHD, psychosis, substance use, and aggressive behavior. Of the two cousins of the index patient's mother, each with an ADHD diagnosis, one had a normal copy number for *FBXO25*, and for the second cousin no results were obtained due to poor quality DNA. Since ADHD is a rather common disorder in the population (Faraone et al., [2015](#jcpp13161-bib-0010){ref-type="ref"}), we can only speculate that there may be additional variants contributing to psychiatric risk (e.g. coming from common variants (Demontis et al., [2019](#jcpp13161-bib-0007){ref-type="ref"}) and/or from environmental risk factors) present in this family, which contribute to the ADHD phenotype in addition to the structural variant. In that way, ADHD may not behave as a strictly monogenic disorder in any of the affected individuals in this pedigree, which is in line with findings from previous rare variant studies of the disorder (Corominas et al., [2018](#jcpp13161-bib-0004){ref-type="ref"}), and reminiscent of findings in previous linkage studies of ADHD (Lesch et al., [2008](#jcpp13161-bib-0033){ref-type="ref"}; Zhou et al., [2008](#jcpp13161-bib-0057){ref-type="ref"}) and other neurodevelopmental disorders (e.g. autism (Chapman et al., [2015](#jcpp13161-bib-0003){ref-type="ref"})). Indeed, WES revealed an additional de novo frameshift variant in the *DUSP16* gene in the index patient, who also showed additional somatic features, anxiety disorder, and psychiatric episodes at very young age. A recent study reported that *Dusp16* plays a critical role in neurogenesis by balancing neural progenitor cell proliferation and neural differentiation (Zega et al., [2017](#jcpp13161-bib-0056){ref-type="ref"}). Moreover, mouse mutants lacking a functional *Dusp16* gene developed fully‐penetrant congenital obstructive hydrocephalus together with brain overgrowth (Zega et al., [2017](#jcpp13161-bib-0056){ref-type="ref"}). When focusing on common genetic variants, we also found nominally significant association of *DUSP16* with schizophrenia. Therefore, it may be suggested that this de novo de novo variant could have a modifying role in the early development of the patient's severe psychiatric phenotypes.

After association testing of the microduplication region in the data from the world‐wide largest genome‐wide association data set on ADHD risk, we identified two genes, the F‐box protein 25 (*FBXO25*) and the testis development‐related protein (*TDRP*) to be associated with ADHD risk. While both genes are expressed in the developing and adult brain, a function in the nervous system has not been described for either, thus far. *FBXO25* codes for an E3 ligase, which provides the substrate specificity for ubiquitin‐dependent destruction or inhibition of transcription factors (Jang et al., [2011](#jcpp13161-bib-0022){ref-type="ref"}). *FBXO25* plays a role in cardiomyocyte development, and reduced expression of *FBXO25* appears to be involved in cell proliferation and migration in nonsmall‐cell lung cancer (Jeong et al., [2015](#jcpp13161-bib-0024){ref-type="ref"}; Jiang et al., [2016](#jcpp13161-bib-0025){ref-type="ref"}). Knockdown of the gene in a cellular system has been linked to decreased phosphorylation of *ERK1*, whereas overexpression has an opposite effect on the MAPK signaling pathway (Teixeira et al., [2017](#jcpp13161-bib-0047){ref-type="ref"}). MAPK signaling plays a role in different psychiatric disorders, including ADHD and autism (Poelmans et al., [2013](#jcpp13161-bib-0041){ref-type="ref"}; Vithayathil et al., [2018](#jcpp13161-bib-0052){ref-type="ref"}). Moreover, the brain relies on ubiquitination to fine‐tune protein content in order to react to new stimuli (Hegde & van Leeuwen, [2017](#jcpp13161-bib-0021){ref-type="ref"}). Another E3 ligase, *FBXO33,* has been the top‐finding of the first case--control genome‐wide association study of persistent ADHD (Sanchez‐Mora et al., [2015](#jcpp13161-bib-0045){ref-type="ref"}). Further F‐box genes have been found associated with neurodevelopmental disorders, too, as for example, reported in a patient with intellectual disability and seizures carrying a deletion of *FBXO28* (Au et al., [2014](#jcpp13161-bib-0002){ref-type="ref"}). Another study reports de novo variants in *FBXO11* in 20 patients, of which 17 show behavioral problems, such as autistic‐like features and ADHD‐related traits (Gregor et al., [2018](#jcpp13161-bib-0016){ref-type="ref"}). *TDRP*, the second gene in the microduplication, is known to be involved in sperm motility (Mao et al., [2016](#jcpp13161-bib-0035){ref-type="ref"}). A rare missense variant in *TDRP* has been reported in monozygotic twins with gender dysphoria (Morimoto et al., [2017](#jcpp13161-bib-0038){ref-type="ref"}). Otherwise, little is known about this gene up to now.

Many different complex behaviors can be studied in *Drosophila*, and it is a model for a wide range of neuropsychiatric phenotypes (van Alphen & van Swinderen, [2013](#jcpp13161-bib-0048){ref-type="ref"}). Among the behaviors that can be robustly assessed in *Drosophila* are locomotor activity and sleep, which are known to undergo a well‐regulated day/night rhythm. These phenotypes have earlier been linked to genes implicated in mania and circadian dysregulation disorders (Guo et al., [2018](#jcpp13161-bib-0018){ref-type="ref"}; Padiath et al., [2004](#jcpp13161-bib-0040){ref-type="ref"}; Ries et al., [2017](#jcpp13161-bib-0044){ref-type="ref"}). In a previous study, we also reported increased activity and decreased sleep upon knockdown of genes that have been highly implicated in ADHD, encoding the dopamine transporter, latrophilin, and neurofibromin 1 (van der Voet et al., [2016](#jcpp13161-bib-0049){ref-type="ref"}). Further experiments strongly suggested this phenotype to result from abnormal activity of the dopaminergic system. Upon overexpression of the *FBXO25* orthologue described here, we recapitulated this phenotype. This demonstrates that overexpression of *FBXO25* in the nervous system is sufficient to trigger increased locomotor activity, suggesting that it can contribute to psychiatric symptoms in our family. This is also the first report providing evidence for FBXO25 having a role in the nervous system.

The findings described here need to be interpreted in light of several strengths and limitations of our study. The main strength of this study is its interdisciplinary setting and comprehensive approach across multiple levels. For this, we integrated complementary evidence from genetic, genomic, and animal model experiments to examine the potential causes of complex psychiatric phenotypes including ADHD segregating across generations in a single family. We combined rare variants approaches (CNV analysis and WES) with an analysis of common variants in the identified CNV using the largest meta‐analysis data sets currently available. For our functional validation of the identified candidate gene *FBXO25*, we used an unconventional, well‐validated animal model. A clear limitation of our study is that another identified candidate gene, *TDRP,* is not conserved in *Drosophila*. We were therefore not able to collect data that would argue for or against a contribution of *TDRP* overexpression to the complex psychiatric phenotypes seen in the family, in addition to *FBXO25*. Similarly, it would be of interest to investigate the role of *DUSP16* as a possible modifier of the phenotype of the index patient. In general, it would be of interest to further assess the specificity of *FBXO25* for ADHD. Given the fact that in this family many other psychiatric traits, cooccurring with ADHD, are present, future studies may want to investigate such cross‐disorder characteristics of *FBXO25*. Also, it has to be tested whether this gene or locus is specifically causal for the common syndrome of ADHD and it may well be informative regarding physiological processes contributing to other neuropsychiatric syndromes, which does merit further in depth exploration to confirm and extend this novel observation.

In conclusion, this study provides an important illustration of the potential of such an across‐species approach and by integrating genetic and genomics studies with biological validation, we identified *FBXO25* as a novel risk gene for ADHD and comorbid psychiatric disorders. This convergence generates novel hypotheses for future studies to discover the underlying molecular mechanisms and identify proteins regulated by FBXO25 in order to better understand the etiology of the aberrant behavior caused by variation in this gene.
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